How to define acceptable changes for QA’s of antibodies

antibodies, QA, Sandoz, qualityattributes


Do you need to ensure that your antibodies are manufactured to a consistent product quality, and therefore guarantee a reproducible clinical performance and acceptable safety profile?

Dr Martin Schiestl, Scientific and Regulatory Advisor at Sandoz contributed to the debate about acceptable changes in quality attributes and how to identify them, when he spoke at the European Antibody Congress 2011. Dr Schiestl delivered three case studies where he evaluated the structure variation of 3 of Sandoz's major marketed biologics: Aranesp (R), Rituxan (R)/ Mabthera(R) and Enbrel(R).

Click here for the full presentation


Do you want to find out more?

How to take an antibody from academic discovery to the patient

How a cancer therapy #antibody target was developed and taken to the clinic

Strategies to enhance #antibody efficacy


For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group:Vaccine Nation

Leave a Reply

Your email address will not be published. Required fields are marked *